News Release

Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: The findings of this study suggest that treatment with bempedoic acid in high-risk primary prevention patients unable to tolerate recommended doses of statins has the potential to reduce major adverse cardiovascular events. 

Authors: Steven E. Nissen, M.D., of the Cleveland Clinic, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.9696)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the American Diabetes Association’s 83rd Scientific Sessions.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.9696?guestAccessKey=5179664e-056a-401a-9bb3-4435a889b053&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062423


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.